Top > Search of International Patents > MEDICINAL COMPOSITION COMPRISING SUGAR CHAIN MODIFYING ENZYME AND METHOD FOR CURING DENDRITIC CELL IMMUNORECEPTOR-RELATED DISEASE USING MEDICINAL COMPOSITION

MEDICINAL COMPOSITION COMPRISING SUGAR CHAIN MODIFYING ENZYME AND METHOD FOR CURING DENDRITIC CELL IMMUNORECEPTOR-RELATED DISEASE USING MEDICINAL COMPOSITION

Foreign code F190009755
File No. (S2017-0734-N0)
Posted date May 7, 2019
Country WIPO
International application number 2018JP018610
International publication number WO 2018207949
Date of international filing May 14, 2018
Date of international publication Nov 15, 2018
Priority data
  • 201762505238 (May 12, 2017) US
Title MEDICINAL COMPOSITION COMPRISING SUGAR CHAIN MODIFYING ENZYME AND METHOD FOR CURING DENDRITIC CELL IMMUNORECEPTOR-RELATED DISEASE USING MEDICINAL COMPOSITION
Abstract A medicinal composition for curing, treating or preventing a disease in which a biological mechanism controlled by a dendritic cell immunoreceptor participates, said medicinal composition comprising a sugar chain modifying enzyme as an active ingredient; and a method for curing, treating or preventing a disease in which a biological mechanism controlled by a dendritic cell immunoreceptor participates.
Outline of related art and contending technology BACKGROUND ART
Dendritic cell immune receptor (Dendritic Cell Immunoreceptor, hereinafter also referred to as a DCIR) is, the major antigen presenting dendritic cells, osteoclasts in the bone-resorbing cells such as cells expressing membrane protein, a sugar chain recognizing extracellular region (CRD) to the domain, the cytoplasmic area in the immunosuppressive signaling motifs (ITIM) with. The inventors of the present disclosure of the above deficient gene DCIR (Dcir - / - mice) is successful in the production of the mouse, the mouse with the age or an adhesive such as an autoimmune disease Sjogren's syndrome flame reported spontaneously developing (for example, JP-2008-29319 and JP-2009-19044 see Japanese Patent Application Laid-Open). In addition, an autoimmune disease Dcir - / - mice model of collagen-induced arthritis in the high sensitivity, which is a dendritic cell for growth and differentiation is an excess of the report (for example, Fujikado et al., nat. med., see 2008).
As described above, the formation of the osteoclasts DCIR, dendritic cell differentiation, proliferation and the inflammatory cytokine production of the negative control is considered to play a role. Accordingly, a ligand which specifically act on the DCIR is founded, the symptoms of the disease and autoimmune disease of bone metabolism and reduction in the relaxation is considered to be an effective means. In addition, dendritic cells are responsible for the immune system can be central, in diseases such as allergy therapeutic effect can be expected. The inventors of the present disclosure based on the above mentioned findings, keratan sulfate (KS-II) - II DCIR is an endogenous ligand that specifically binds to as SHP-1 into osteoclasts found via the signaling (for example, International Publication No. 2011/105424 are incorporated by reference). Further the inventors of the present disclosure, a specific chemical structure N-type double-stranded asialo DCIR specifically act on the sugar chain was found to be a ligand (International Publication No. 2016/006700 are incorporated by reference).
Scope of claims (In Japanese)請求の範囲 [請求項1]
 樹状細胞免疫受容体によって制御される生体機構が関与する疾患を治療、処置、または予防するための医薬組成物であって、糖鎖修飾酵素を有効成分として含む、前記医薬組成物。

[請求項2]
 前記糖鎖修飾酵素がノイラミニダーゼである、請求項1に記載の医薬組成物。

[請求項3]
 前記疾患が骨代謝疾患、自己免疫疾患またはアレルギー疾患である、請求項1又は請求項2に記載の医薬組成物。

[請求項4]
 前記疾患が骨粗しょう症、関節リウマチまたは多発性硬化症である、請求項1~請求項3のいずれか1項に記載の医薬組成物。

[請求項5]
 前記疾患を有する対象に、前記糖鎖修飾酵素が治療上、処置上、または予防上有効量となる用量及び間隔で投与される、請求項1~請求項4のいずれか1項に記載の医薬組成物。

[請求項6]
 樹状細胞免疫受容体によって制御される生体機構が関与する疾患の治療、処置、または予防を必要とする対象に、有効量の糖鎖修飾酵素を投与することを含む、前記疾患を治療、処置、または予防する方法。

[請求項7]
 前記糖鎖修飾酵素がノイラミニダーゼである、請求項6に記載の方法。

[請求項8]
 前記疾患が骨代謝疾患、自己免疫疾患またはアレルギー疾患である、請求項6又は請求項7に記載の方法。

[請求項9]
 前記疾患が骨粗しょう症、関節リウマチまたは多発性硬化症である、請求項6~請求項8のいずれか1項に記載の方法。

[請求項10]
 前記疾患を有する対象に、前記糖鎖修飾酵素が治療上、処置上、または予防上有効量となる用量及び間隔で投与することを含む、請求項6~請求項9のいずれか1項に記載の方法。

[請求項11]
 前記投与が経口投与、皮下投与、腹腔内投与、筋肉内投与、点眼、点耳、経鼻投与、吸入投与、経皮投与、経直腸投与、髄腔内投与、または静脈内投与である、請求項6~請求項10のいずれか1項に記載の方法。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOKYO UNIVERSITY OF SCIENCE
  • Inventor
  • IWAKURA, Yoichiro
  • KAIFU, Tomonori
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close